Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy

Background and Objective: Ibrutinib has recently been approved in Europe for Waldenström Macroglobulinemia (WM) in symptomatic patients who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemo-immunotherapy. The aim of the study is to estimate the in...

Descripción completa

Detalles Bibliográficos
Autores principales: Aiello, Andrea, D’Ausilio, Anna, Lo Muto, Roberta, Randon, Francesca, Laurenti, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Routledge 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700492/
https://www.ncbi.nlm.nih.gov/pubmed/29201288
http://dx.doi.org/10.1080/20016689.2017.1393308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700492/
https://www.ncbi.nlm.nih.gov/pubmed/29201288
http://dx.doi.org/10.1080/20016689.2017.1393308

Ejemplares similares